James A. Totterdell

15 Hospital Ave
Nedlands, WA 6009, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

The AuTOMATIC trial: a multicentre digitally-automated, Bayesian, adaptive, parallel, factorial randomised controlled trial of SMS reminders for childhood vaccination.

The AuTOMATIC trial: a multicentre digitally-automated, Bayesian, adaptive, parallel, factorial randomised controlled trial of SMS reminders for childhood vaccination.

Journal: The Lancet regional health. Western Pacific

Published: November 12, 2025

ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations.

ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations.

Journal: Trials

Published: October 14, 2025

Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines.

Immune impacts of infant whole-cell and acellular pertussis vaccination on co-administered vaccines.

Journal: The Journal of infection

Published: March 02, 2025

Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.

Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.

Journal: Annals of internal medicine

Published: December 23, 2024

FeBRILe3: Risk-Stratification and Diagnosis of Serious Bacterial Infections in Febrile Infants Less Than 3 Months Old.

FeBRILe3: Risk-Stratification and Diagnosis of Serious Bacterial Infections in Febrile Infants Less Than 3 Months Old.

Journal: Journal of paediatrics and child health

Published: December 02, 2024

Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.

Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.

Journal: BMJ open

Published: October 22, 2024

Erratum to 'TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate' [Clin Microbiol Infect (30) (2024) 743-754].

Erratum to 'TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate' [Clin Microbiol Infect (30) (2024) 743-754].

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: August 09, 2024

Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study.

Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study.

Journal: Trials

Published: February 28, 2024

A Randomized Trial of Nafamostat for Covid-19.

A Randomized Trial of Nafamostat for Covid-19.

Journal: NEJM evidence

Published: February 06, 2024

Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19.

Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19.

Journal: NEJM evidence

Published: February 06, 2024

Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.

Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.

Journal: PLoS medicine

Published: January 18, 2024

TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.

TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: December 05, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026